This technology is currently not available for licensing
Tech ID: 22934
Additional Technologies by these Inventors
- Suppression of sPLA2-Integrin Binding for Treating an Inflammatory Condition or Suppressing Cell Proliferation
- Development of Dominant Negative CD40L Antagonists DACD40L
- Novel Insight into Inhibiting IGF1 Signaling
- The Isolated Heparin-binding Domain (HBD) of VEGF165 and the Isolated D1 Domain of VEGFR2 (KDR)
- Novel Fibroblast Growth Factor 1-Derived Peptides for Therapy and Drug Discovery
- Modulating MD-2-Integrin Interaction for Sepsis Treatment
- Integrin Binding to P-Selectin as a Treatment for Cancer and Inflammation
